Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it will present a company overview at the 2018 Biotech Showcase on Tuesday, January 9, 2018 at 4:00 p.m. pacific time in San Francisco.
To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, with programs in acute myeloid leukemia and immuno-oncology. Mateon is committed to leveraging its product development expertise and intellectual property to bring improved and medically necessary new therapies to cancer patients worldwide.
CONTACTS
Investors:
Mateon Therapeutics, Inc.
Matthew M. Loar
[email protected]
650-635-7000
